k141_139993_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.2	115	929	228	9.13e-10	58.9
k141_139993_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.3	114	929	232	1.57e-06	49.3
k141_139993_10	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.3	416	1031	1197	1.16e-43	171
k141_917140_3	SARG|NC_011595.7058890.p01	30.0	453	473	468	1.69e-62	209
k141_917140_3	NCBI|AAY90615.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	27.9	473	473	486	2.48e-39	147
k141_917140_3	SARG|NC_008702.1.4606278.p01	28.2	464	473	467	4.87e-39	146
k141_917140_3	CARD|gb|AAX14803.1|ARO:3000782|adeK	27.3	465	473	484	8.05e-38	143
k141_917140_3	NCBI|AAQ92182.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	27.9	463	473	486	3.72e-36	138
k141_917140_3	SARG|gi|1399759|gb|AAB41958.1|	28.0	382	473	479	5.36e-26	109
k141_917140_3	SARG|gi|553768013|ref|WP_023100243.1|	28.0	382	473	479	9.77e-26	108
k141_917140_3	SARG|YP_002090521	28.0	382	473	479	9.77e-26	108
k141_917140_3	SARG|gi|759363558|ref|WP_043092439.1|	28.0	382	473	479	9.77e-26	108
k141_917140_3	SARG|NC_002516.2.881070.p01	28.0	382	473	479	9.77e-26	108
k141_917140_4	SARG|gi|1035670474|ref|WP_064517458.1|	55.2	650	654	648	2.16e-237	671
k141_917140_4	SARG|gi|1035717981|ref|WP_064557480.1|	55.2	650	654	648	2.16e-237	671
k141_917140_4	SARG|gb|AAV85982.1|ARO:3000535|macB	54.5	649	654	644	7.58e-237	669
k141_917140_4	SARG|gi|746253210|ref|WP_039301529.1|	55.5	652	654	648	3.51e-236	668
k141_917140_4	SARG|gi|736472622|ref|WP_034494292.1|	55.4	653	654	648	4.98e-236	667
k141_917140_4	SARG|gi|495736522|ref|WP_008461101.1|	55.5	652	654	648	7.05e-236	667
k141_917140_4	SARG|gi|746243059|ref|WP_039291473.1|	55.2	650	654	648	1.42e-235	666
k141_917140_4	SARG|gi|1001720867|ref|WP_061274204.1|	55.1	650	654	648	1.42e-235	666
k141_917140_4	SARG|gi|446110286|ref|WP_000188141.1|	54.3	650	654	648	1.42e-235	666
k141_917140_4	SARG|gi|639225329|ref|WP_024561799.1|	55.1	653	654	648	2.01e-235	666
k141_917140_5	SARG|gi|487980711|ref|WP_002053440.1|	37.2	438	395	446	6.60e-79	249
k141_917140_5	SARG|gi|490848588|ref|WP_004710651.1|	37.2	438	395	446	6.60e-79	249
k141_917140_5	SARG|gi|518287882|ref|WP_019458090.1|	36.4	440	395	446	4.04e-77	244
k141_917140_5	SARG|gi|559226183|ref|WP_023581296.1|	39.7	370	395	369	2.28e-75	237
k141_917140_5	SARG|gi|857776688|emb|CRL63266.1|	40.2	361	395	358	2.34e-75	237
k141_917140_5	SARG|gi|857587769|emb|CRL59467.1|	40.4	366	395	369	4.54e-75	236
k141_917140_5	SARG|gi|739066754|ref|WP_036938162.1|	40.0	370	395	369	4.54e-75	236
k141_917140_5	SARG|gi|490836655|ref|WP_004698731.1|	37.8	439	395	445	1.45e-73	235
k141_917140_5	SARG|gi|983379772|ref|WP_060557066.1|	40.3	352	395	369	1.99e-73	232
k141_917140_5	SARG|gi|1036665709|ref|WP_064719478.1|	38.9	375	395	369	2.81e-73	232
k141_917154_2	SARG|gi|757781454|ref|WP_043000038.1|	31.3	268	318	660	1.56e-35	134
k141_917154_2	SARG|gi|507079934|ref|WP_016150692.1|	31.3	268	318	660	3.96e-35	133
k141_917154_2	SARG|YP_002850217	31.0	268	318	660	1.01e-34	132
k141_917154_2	SARG|gi|757799830|ref|WP_043017032.1|	31.0	268	318	660	1.01e-34	132
k141_917154_2	SARG|gi|851935911|ref|WP_048224705.1|	31.0	268	318	660	1.37e-34	132
k141_917154_2	SARG|gi|851965596|ref|WP_048234849.1|	31.0	268	318	660	1.37e-34	132
k141_917154_2	SARG|gi|851917461|ref|WP_048217311.1|	31.0	268	318	660	1.87e-34	131
k141_917154_2	SARG|gi|507086291|ref|WP_016157032.1|	31.3	268	318	660	1.87e-34	131
k141_917154_2	SARG|gi|489117806|ref|WP_003027650.1|	31.0	268	318	660	1.87e-34	131
k141_917154_2	SARG|gi|765458296|ref|WP_044714032.1|	31.0	268	318	660	1.87e-34	131
k141_917154_28	SARG|FN594949.1.gene24.p01	48.5	134	615	640	4.70e-26	112
k141_917154_28	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	48.5	134	615	640	4.70e-26	112
k141_917154_28	SARG|ABV82118	46.3	134	615	639	1.90e-24	107
k141_917154_28	SARG|ZP_03989103	46.3	134	615	639	2.52e-24	106
k141_917154_28	SARG|ABV82120	46.3	134	615	639	2.52e-24	106
k141_917154_34	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.8	220	417	255	4.15e-38	137
k141_917154_34	SARG|gi|895865878|ref|WP_048974758.1|	31.5	222	417	646	2.47e-25	107
k141_917154_34	SARG|gi|639209604|ref|WP_024547784.1|	33.5	221	417	648	1.46e-24	105
k141_917154_34	SARG|gi|447195836|ref|WP_001273092.1|	28.9	218	417	306	9.02e-22	94.0
k141_917154_34	SARG|gi|447195835|ref|WP_001273091.1|	28.4	218	417	306	2.29e-21	92.8
k141_917154_34	SARG|ZP_04081918	28.0	214	417	306	2.29e-21	92.8
k141_917154_34	SARG|gi|500448961|gb|EOP61695.1|	28.0	214	417	306	4.25e-21	92.0
k141_917154_34	SARG|gi|500194536|ref|WP_011867743.1|	28.5	214	417	306	4.25e-21	92.0
k141_917154_34	SARG|gi|500465078|gb|EOP76697.1|	28.0	214	417	306	5.79e-21	91.7
k141_917154_35	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	42.7	75	220	210	1.28e-16	74.3
k141_917154_35	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	42.7	75	220	210	1.28e-16	74.3
k141_917154_36	SARG|CAC35724	47.1	399	398	399	3.58e-109	325
k141_917154_36	SARG|YP_002848373	46.9	388	398	414	4.62e-108	323
k141_917154_36	SARG|gi|817634809|ref|WP_046606162.1|	46.4	388	398	397	2.17e-107	320
k141_917154_36	SARG|CAR60299	46.4	388	398	397	3.07e-107	320
k141_917154_36	SARG|gi|489927712|ref|WP_003831044.1|	46.6	388	398	397	3.07e-107	320
k141_917154_36	SARG|gi|696364907|ref|WP_032939988.1|	46.6	388	398	397	4.34e-107	320
k141_917154_36	SARG|ZP_02656523	46.4	388	398	397	6.14e-107	319
k141_917154_36	SARG|gi|749610452|ref|WP_040232688.1|	46.9	373	398	397	8.69e-107	319
k141_917154_36	SARG|gi|817604003|ref|WP_046597369.1|	46.1	388	398	397	1.23e-106	318
k141_917154_36	SARG|CP000647.1.gene444.p01	47.3	387	398	397	1.23e-106	318
k141_917154_37	SARG|gi|447196024|ref|WP_001273280.1|	57.7	1056	1078	1037	0.0	1147
k141_917154_37	SARG|gi|487663012|ref|WP_001752778.1|	57.5	1056	1078	1037	0.0	1145
k141_917154_37	SARG|gi|817600095|ref|WP_046594084.1|	57.5	1056	1078	1037	0.0	1142
k141_917154_37	SARG|gi|817601660|ref|WP_046595348.1|	57.6	1056	1078	1037	0.0	1142
k141_917154_37	SARG|gi|817604860|ref|WP_046598079.1|	57.5	1056	1078	1037	0.0	1142
k141_917154_37	SARG|gi|817600173|ref|WP_046594139.1|	57.5	1056	1078	1037	0.0	1141
k141_917154_37	CARD|gb|AAC73564.1|ARO:3000216|acrB	57.1	1055	1078	1049	0.0	1138
k141_917154_37	SARG|CP000647.1.gene3710.p01	56.6	1056	1078	1036	0.0	1132
k141_917154_37	SARG|gi|556290479|ref|WP_023291164.1|	56.8	1056	1078	1036	0.0	1132
k141_917154_37	SARG|gi|694076105|ref|WP_032421853.1|	56.6	1056	1078	1036	0.0	1132
k141_917154_38	NCBI|AAQ92182.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	42.2	469	465	486	1.54e-114	344
k141_917154_38	NCBI|AAY90615.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	42.9	471	465	486	8.68e-114	342
k141_917154_38	NCBI|AAD15665.1|1|1|tbtM|tbtM||1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_outer_membrane_channel_subunit_TbtM|AMR|efflux	41.3	465	465	476	1.62e-105	321
k141_917154_38	SARG|YP_002083353	39.2	477	465	485	7.11e-97	299
k141_917154_38	SARG|NC_008702.1.4606278.p01	39.5	461	465	467	1.67e-96	297
k141_917154_38	SARG|CP001138.1.gene376.p01	40.1	469	465	485	7.90e-96	296
k141_917154_38	SARG|gi|553757603|ref|WP_023090259.1|	38.8	477	465	485	3.12e-95	295
k141_917154_38	SARG|NC_002516.2.877851.p01	38.8	477	465	485	3.12e-95	295
k141_917154_38	SARG|YP_001345922	38.8	474	465	485	6.21e-95	294
k141_917154_38	SARG|gi|353074765|gb|EHB40525.1|	39.9	469	465	496	1.20e-94	293
k141_479350_11	ResF|penA_1_AF515059_1	35.4	571	576	581	1.30e-117	359
k141_479350_11	SARG|gb|AQX82857.1|ARO:3004185|mecD	25.3	526	576	678	7.43e-19	89.4
k141_479350_12	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	21.5	363	484	481	4.79e-09	57.4
k141_479350_12	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	21.7	360	484	451	9.96e-08	53.1
k141_479350_13	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.7	462	453	451	4.28e-59	199
k141_479350_13	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	31.3	460	453	481	6.01e-59	199
k141_479350_13	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	29.7	458	453	451	6.54e-57	193
k141_479350_32	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.1	502	582	1033	7.08e-29	121
k141_479350_32	SARG|gb|AEY83581|ARO:3000510|mupB	22.1	502	582	1033	7.08e-29	121
k141_479350_32	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	21.7	507	582	1024	2.20e-28	119
k141_479350_32	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.7	507	582	1024	2.20e-28	119
k141_479350_32	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.7	507	582	1024	6.90e-28	118
k141_479350_32	SARG|gb|CAA53189|ARO:3000521|mupA	21.7	507	582	1024	6.90e-28	118
k141_599056_7	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	25.4	197	377	314	2.51e-14	72.0
k141_439949_3	SARG|gi|542061059|gb|ERI11611.1|	27.2	202	492	316	3.69e-12	66.2
k141_439949_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	22.9	210	492	307	8.79e-08	52.8
k141_439949_3	SARG|M57437.gene.p01	26.5	223	492	548	1.54e-07	52.8
k141_439949_11	CARD|gb|BAE77933.1|ARO:3000518|CRP	83.0	212	213	210	1.47e-125	352
k141_479868_4	CARD|gb|AAK37618.1|ARO:3005008|TxR	35.7	333	476	318	4.85e-60	198
k141_479868_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.4	113	476	228	5.82e-12	64.3
k141_479868_4	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	29.7	118	476	225	6.78e-10	58.2
k141_479868_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.9	107	476	219	1.25e-08	54.3
k141_479868_7	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.3	399	734	1197	3.05e-45	174
k141_479868_7	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	26.1	119	734	231	8.77e-07	49.7
k141_479868_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.7	101	734	228	1.14e-06	49.3
k141_479868_7	CARD|gb|AAD51348.1|ARO:3003066|smeR	26.7	101	734	229	1.15e-06	49.3
k141_479868_7	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	26.1	119	734	231	1.58e-06	48.9
k141_479868_7	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	28.3	106	734	225	2.68e-06	48.1
k141_479868_7	CARD|gb|AAC73788.1|ARO:3003841|kdpE	28.3	106	734	225	2.68e-06	48.1
k141_479868_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	26.1	119	734	231	3.81e-06	47.8
k141_479868_7	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	26.1	119	734	231	3.81e-06	47.8
k141_101805_11	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	23.3	326	620	579	2.16e-13	72.0
k141_101805_11	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.2	313	620	579	3.77e-13	71.2
k141_101805_11	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	25.9	247	620	578	1.85e-11	65.9
k141_241369_11	CARD|gb|BAB41874.1|ARO:3000815|mgrA	29.9	144	148	147	2.36e-20	80.5
k141_818994_10	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	39.0	508	528	533	1.03e-94	297
k141_818994_10	SARG|AF353562.gene.p01	37.2	355	528	369	1.91e-56	192
k141_818994_19	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	31.1	257	332	314	3.14e-34	126
k141_818994_19	SARG|AY082011.1.gene6.p01	34.1	270	332	323	5.41e-32	120
k141_818994_19	SARG|gi|746609237|ref|WP_039635344.1|	31.0	261	332	322	7.39e-32	120
k141_818994_19	SARG|gi|552942232|ref|WP_023043160.1|	34.1	270	332	323	1.05e-31	120
k141_818994_19	SARG|gi|740152780|ref|WP_037997109.1|	31.1	257	332	322	2.76e-31	119
k141_818994_19	SARG|AF155139.2.gene6.p01	31.7	262	332	322	2.76e-31	119
k141_818994_19	SARG|NP_878015	31.9	248	332	322	3.84e-31	118
k141_818994_19	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	30.5	259	332	322	1.43e-30	117
k141_818994_19	SARG|gi|749574782|ref|WP_040203616.1|	31.2	263	332	323	1.46e-30	117
k141_818994_19	SARG|DQ018711.1.gene4.p01	29.9	261	332	322	1.03e-29	114
k141_102788_9	SARG|DQ018711.1.gene4.p01	36.5	233	411	322	2.19e-29	115
k141_102788_9	SARG|gi|738848198|ref|WP_036737307.1|	36.1	233	411	323	4.01e-28	112
k141_102788_9	SARG|gi|737310392|ref|WP_035293250.1|	35.6	233	411	323	1.44e-27	110
k141_102788_9	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	30.8	279	411	337	3.45e-27	109
k141_102788_9	SARG|gi|746609237|ref|WP_039635344.1|	36.1	230	411	322	2.49e-26	107
k141_102788_9	SARG|AF155139.2.gene6.p01	35.2	230	411	322	1.00e-23	99.8
k141_699759_5	SARG|gi|671541568|ref|WP_031525212.1|	34.8	224	231	648	1.15e-32	123
k141_699759_5	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	26.1	211	231	528	4.29e-08	52.0
k141_3619_2	SARG|gi|447057509|ref|WP_001134765.1|	29.4	296	308	309	2.88e-36	131
k141_3619_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	28.9	228	308	343	5.85e-36	131
k141_3619_2	SARG|gi|445996719|ref|WP_000074574.1|	29.4	296	308	309	7.87e-36	130
k141_3619_2	SARG|gi|447057510|ref|WP_001134766.1|	29.1	296	308	309	3.01e-35	128
k141_3619_2	SARG|gi|445996722|ref|WP_000074577.1|	29.7	296	308	309	8.20e-35	127
k141_3619_2	SARG|gi|884875933|emb|CKG93789.1|	30.1	296	308	309	1.15e-34	127
k141_3619_2	SARG|gi|445996723|ref|WP_000074578.1|	29.4	296	308	309	1.15e-34	127
k141_3619_2	SARG|gi|488068784|ref|WP_002140181.1|	28.7	296	308	309	1.15e-34	127
k141_3619_2	SARG|gi|542061059|gb|ERI11611.1|	29.1	296	308	316	1.33e-34	127
k141_3619_2	SARG|gi|488067981|ref|WP_002139378.1|	28.7	296	308	309	1.60e-34	126
k141_600889_4	NCBI|KGT34314.1|1|1|catC|catC|acetyltransferase|1|CHLORAMPHENICOL|PHENICOL|type_C_phenicol_O-acetyltransferase|AMR|phenicol	34.7	72	457	219	6.03e-06	46.2
k141_760302_4	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	35.5	633	878	703	3.63e-103	334
k141_820603_14	SARG|YP_594556	25.4	456	603	639	1.39e-26	113
k141_820603_14	SARG|AAV80410	23.8	458	603	651	4.54e-26	112
k141_820603_14	SARG|ABN80187	25.1	462	603	640	1.38e-25	110
k141_820603_14	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	24.3	461	603	639	1.82e-25	110
k141_820603_14	SARG|ABN79417	25.1	454	603	639	1.82e-25	110
k141_820603_14	SARG|AAO42740	25.1	454	603	639	1.82e-25	110
k141_820603_14	SARG|AY485126.gene.p01	25.1	454	603	639	1.82e-25	110
k141_820603_14	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.1	454	603	639	1.82e-25	110
k141_820603_14	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	25.1	458	603	639	2.43e-25	109
k141_820603_14	SARG|ABF69686	25.1	458	603	639	2.43e-25	109
k141_521907_6	CARD|gb|AAK37618.1|ARO:3005008|TxR	51.0	151	270	318	7.84e-44	150
k141_183967_6	SARG|gb|AAC75089.1|ARO:3003577|ugd	59.1	389	390	388	3.19e-168	474
k141_183967_16	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.4	208	213	204	3.51e-25	96.7
k141_183967_16	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.1	183	213	219	3.22e-09	53.9
k141_183967_16	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.1	183	213	219	3.22e-09	53.9
k141_183967_16	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.1	183	213	220	3.25e-09	53.9
k141_183967_16	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.1	183	213	220	4.45e-09	53.5
k141_183967_16	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	24.6	183	213	220	1.54e-08	52.0
k141_183967_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	24.1	162	213	228	2.63e-07	48.5
k141_183967_16	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.2	123	213	219	2.10e-06	45.8
k141_183967_16	CARD|gb|AAG06465.1|ARO:3005063|cprR	26.6	128	213	223	2.15e-06	45.8
k141_183967_16	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	27.0	115	213	232	2.27e-06	45.8
k141_761476_8	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	43.5	1370	1345	1186	0.0	1011
k141_761476_8	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	43.5	1370	1345	1186	0.0	1011
k141_761476_8	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	43.2	1363	1345	1162	0.0	1003
k141_562059_2	SARG|YP_264987	34.3	274	276	280	5.99e-38	134
k141_562059_2	SARG|YP_581244	33.6	274	276	280	2.49e-36	129
k141_562059_2	SARG|YP_001563294	29.7	269	276	275	4.36e-36	129
k141_562059_2	SARG|ZP_03552050	29.4	272	276	274	4.55e-35	126
k141_562059_2	SARG|ZP_03541894	29.0	269	276	274	6.39e-35	125
k141_562059_2	SARG|YP_316450	32.2	276	276	276	1.31e-34	125
k141_562059_2	SARG|YP_523088	29.8	275	276	277	3.70e-34	124
k141_562059_2	SARG|ZP_03054084	28.8	271	276	302	6.40e-34	124
k141_562059_2	SARG|YP_985461	29.4	272	276	274	6.79e-34	123
k141_562059_2	SARG|YP_002552549	29.4	269	276	274	1.33e-33	122
k141_224323_10	SARG|AUI09862.1	43.4	272	286	287	2.16e-69	215
k141_224323_10	SARG|AJ459418.gene.p01	38.5	257	286	263	6.15e-51	167
k141_224323_10	SARG|gi|970263436|ref|WP_058647620.1|	38.5	257	286	263	8.68e-51	167
k141_224323_10	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	33.3	255	286	271	3.28e-42	145
k141_224323_10	SARG|gi|487670925|ref|WP_001756235.1|	33.3	255	286	271	4.62e-42	144
k141_224323_10	SARG|gi|486033774|ref|WP_001505252.1|	33.3	255	286	271	6.49e-42	144
k141_224323_10	SARG|DQ464881.1.gene2.p01	33.3	255	286	271	1.28e-41	143
k141_224323_10	SARG|gi|638947703|ref|WP_024439711.1|	32.9	255	286	271	1.81e-41	143
k141_224323_10	SARG|gi|916164813|ref|WP_050960181.1|	32.9	255	286	271	1.81e-41	143
k141_224323_10	SARG|gi|446966006|ref|WP_001043262.1|	32.9	255	286	271	1.81e-41	143
k141_264824_14	SARG|NC_008702.1.4608931.p01	26.4	473	506	473	3.79e-40	150
k141_264824_14	SARG|gi|553774750|ref|WP_023106587.1|	26.4	421	506	472	1.41e-33	131
k141_264824_14	SARG|gi|686099038|ref|WP_031755887.1|	26.4	421	506	472	1.41e-33	131
k141_264824_14	SARG|gi|685898668|ref|WP_031639304.1|	26.4	421	506	472	1.41e-33	131
k141_264824_14	SARG|gi|730274062|ref|WP_033966812.1|	26.4	421	506	472	1.41e-33	131
k141_264824_14	SARG|gi|553765230|ref|WP_023097551.1|	26.4	421	506	472	1.41e-33	131
k141_264824_14	SARG|YP_790742	26.4	421	506	472	1.93e-33	131
k141_264824_14	SARG|gi|504415764|ref|WP_014602866.1|	26.4	421	506	472	1.93e-33	131
k141_264824_14	SARG|gi|553756495|ref|WP_023089177.1|	26.4	421	506	472	1.93e-33	131
k141_264824_14	SARG|NC_002516.2.882885.p01	26.4	421	506	472	1.93e-33	131
k141_264824_16	SARG|YP_001373621	40.9	232	913	318	1.13e-45	166
k141_264824_16	SARG|P42332	40.1	232	913	306	1.16e-43	159
k141_264824_16	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	40.1	232	913	306	1.16e-43	159
k141_264824_16	SARG|gi|510143239|gb|AGN36970.1|	40.1	232	913	313	1.39e-43	159
k141_264824_16	SARG|ABB80128	40.1	232	913	306	2.15e-43	159
k141_264824_16	SARG|gi|542061059|gb|ERI11611.1|	40.1	232	913	316	2.78e-43	159
k141_264824_16	SARG|gi|445996732|ref|WP_000074587.1|	39.7	232	913	309	3.16e-43	158
k141_264824_16	SARG|AAD21213	39.7	232	913	306	7.38e-43	157
k141_264824_16	SARG|gi|488068784|ref|WP_002140181.1|	40.2	224	913	309	7.97e-43	157
k141_264824_16	SARG|gi|487936534|ref|WP_002010000.1|	39.7	224	913	309	1.08e-42	157
k141_264824_20	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.8	213	231	550	8.44e-11	60.1
k141_264824_25	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.4	189	260	255	2.44e-36	128
k141_264824_25	SARG|gi|445996719|ref|WP_000074574.1|	29.8	235	260	309	2.25e-27	106
k141_264824_25	SARG|gi|895808656|emb|COR83787.1|	29.4	235	260	309	3.14e-27	105
k141_264824_25	SARG|gi|445996723|ref|WP_000074578.1|	29.8	235	260	309	4.37e-27	105
k141_264824_25	SARG|gi|445996722|ref|WP_000074577.1|	29.8	235	260	309	6.08e-27	105
k141_264824_25	SARG|gi|507023808|ref|WP_016095885.1|	29.4	235	260	309	8.46e-27	104
k141_264824_25	SARG|gi|445996710|ref|WP_000074565.1|	29.8	235	260	309	8.46e-27	104
k141_264824_25	SARG|gi|445996729|ref|WP_000074584.1|	29.8	235	260	309	1.18e-26	104
k141_264824_25	SARG|gi|1043490477|ref|WP_065382463.1|	29.4	235	260	309	1.18e-26	104
k141_264824_25	SARG|gi|445996726|ref|WP_000074581.1|	29.4	235	260	309	1.18e-26	104
k141_264824_28	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	37.3	193	243	255	2.10e-36	128
k141_264824_28	SARG|gi|446048013|ref|WP_000125868.1|	35.7	210	243	648	3.44e-33	125
k141_264824_28	SARG|YP_001571041	37.6	181	243	648	6.43e-33	124
k141_264824_28	SARG|gi|960873409|ref|WP_058345546.1|	37.6	181	243	648	6.43e-33	124
k141_264824_28	SARG|gi|779838942|ref|WP_045343641.1|	37.6	181	243	648	8.79e-33	124
k141_264824_28	SARG|gi|959866458|ref|WP_058145168.1|	37.6	181	243	648	8.79e-33	124
k141_264824_28	SARG|gi|810369244|ref|WP_046334012.1|	37.6	181	243	647	1.20e-32	124
k141_264824_28	SARG|gi|555246906|ref|WP_023230855.1|	37.6	181	243	648	1.20e-32	124
k141_264824_28	SARG|gi|950834222|ref|WP_057524365.1|	37.6	181	243	648	1.20e-32	124
k141_264824_28	SARG|YP_002044935	37.6	181	243	648	1.20e-32	124
k141_204595_3	megares|MEG_1004|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT9_1	81.2	154	155	269	3.42e-87	254
k141_204595_3	NCBI|WP_002294509.1|1|1|spw|spw|nucleotidyltransferase|2|aminoglycoside|aminoglycoside|ANT(9)_family_aminoglycoside_nucleotidyltransferase_Spw|AMR|aminoglycoside	81.2	154	155	269	3.42e-87	254
k141_204595_3	SARG|AAX54909	64.1	153	155	260	1.69e-68	207
k141_204595_3	NCBI|WP_002578722.1|1|1|aad9|aad9|nucleotidyltransferase|2|aminoglycoside|aminoglycoside|ANT(9)_family_aminoglycoside_nucleotidyltransferase|AMR|aminoglycoside	51.3	152	155	258	5.02e-49	157
k141_204595_3	SARG|gb|QEQ43477.1|ARO:3005062|ANT(3'')-Ib	44.2	154	155	266	2.27e-43	143
k141_204595_3	NCBI|WP_021586183.1|1|1|ant(9)-Ic|ant(9)-Ic|nucleotidyltransferase|2|SPECTINOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(9)-Ic|AMR|aminoglycoside	45.8	131	155	259	5.97e-39	131
k141_204595_3	NCBI|WP_031942898.1|1|1|aadA1|aadA1|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1|AMR|aminoglycoside	40.0	150	155	263	1.41e-34	120
k141_204595_3	NCBI|WP_071846372.1|1|1|aadA1|aadA1|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1|AMR|aminoglycoside	40.7	150	155	263	2.80e-34	119
k141_204595_3	megares|MEG_965|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME_1	40.0	150	155	224	1.73e-33	116
k141_204595_3	NCBI|WP_071846224.1|1|1|aadA1|aadA1|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1|AMR|aminoglycoside	40.0	150	155	263	3.08e-33	117
k141_204595_4	SARG|gi|496675169|ref|WP_009317659.1|	99.5	405	406	405	4.15e-277	751
k141_204595_4	SARG|gi|492342289|ref|WP_005816151.1|	99.3	405	406	405	6.88e-276	748
k141_204595_4	SARG|gi|653615298|ref|WP_027625762.1|	99.3	405	406	405	6.88e-276	748
k141_204595_4	SARG|gi|495112610|ref|WP_007837430.1|	99.3	405	406	405	1.39e-275	748
k141_204595_4	SARG|gi|496592990|ref|WP_009288847.1|	99.0	405	406	408	4.45e-275	746
k141_204595_4	SARG|gi|748788175|ref|WP_040036560.1|	98.5	405	406	405	9.35e-274	743
k141_204595_4	SARG|YP_001396002	98.5	405	406	408	1.05e-273	743
k141_204595_4	SARG|gi|746176741|ref|WP_039236476.1|	98.3	405	406	408	2.11e-273	742
k141_204595_4	SARG|gi|496263491|ref|WP_008976876.1|	98.3	405	406	405	5.40e-273	741
k141_204595_4	SARG|gi|496540795|ref|WP_009246943.1|	98.3	405	406	405	1.09e-272	740
k141_723416_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.8	207	258	255	1.95e-38	134
k141_723416_2	SARG|gb|AAV85982.1|ARO:3000535|macB	39.3	201	258	644	1.68e-29	115
k141_723416_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	28.8	212	258	258	9.19e-23	92.8
k141_165236_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.5	222	269	258	4.34e-23	94.0
k141_165236_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	22.7	229	269	648	1.02e-06	48.5
k141_165236_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.6	222	341	255	2.89e-15	73.6
k141_165236_3	SARG|gi|495067432|ref|WP_007792257.1|	25.8	217	341	647	1.14e-12	67.8
k141_165236_3	SARG|gi|803568669|ref|WP_046077412.1|	26.9	216	341	648	6.45e-12	65.5
k141_165236_3	SARG|gi|446110352|ref|WP_000188207.1|	26.9	216	341	648	6.45e-12	65.5
k141_165236_3	SARG|YP_002382193	26.9	216	341	648	6.45e-12	65.5
k141_165236_3	SARG|gi|803575554|ref|WP_046081557.1|	26.9	216	341	648	6.45e-12	65.5
k141_165236_3	SARG|gi|446110351|ref|WP_000188206.1|	26.9	216	341	648	6.45e-12	65.5
k141_165236_3	SARG|gi|695840638|ref|WP_032753940.1|	25.5	243	341	646	2.72e-11	63.5
k141_165236_3	SARG|gi|696411918|ref|WP_032982657.1|	25.3	217	341	647	3.62e-11	63.2
k141_165236_3	SARG|gi|507086196|ref|WP_016156937.1|	24.3	255	341	648	4.83e-11	62.8
k141_165236_8	SARG|ZP_02848503	26.3	190	568	221	4.50e-10	58.9
k141_165236_8	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.3	127	568	232	7.59e-09	55.5
k141_165236_8	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.7	120	568	247	2.17e-08	54.3
k141_165236_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	27.9	147	568	231	1.54e-06	48.5
k141_165236_10	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.6	340	1145	1197	8.42e-35	143
k141_622813_34	SARG|gb|BAH45481.1|ARO:3002815|clbB	36.5	345	374	343	1.55e-58	192
k141_622813_34	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	35.1	367	374	379	4.29e-57	189
k141_622813_34	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	36.8	348	374	416	4.09e-56	188
k141_622813_34	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	34.0	359	374	349	4.09e-52	176
k141_622813_34	SARG|CP001581.1.gene3143.p01	34.0	341	374	344	5.07e-52	175
k141_622813_34	SARG|AJ249217.gene.p01	34.0	359	374	349	1.13e-51	174
k141_622813_34	SARG|gb|ACX65640.1|ARO:3003907|cipA	34.0	347	374	346	2.90e-51	173
k141_622813_34	SARG|gb|BAD63613.1|ARO:3002816|clbC	34.5	351	374	350	1.24e-50	172
k141_622813_34	SARG|gb|AGZ55247.1|ARO:3002814|clbA	33.7	344	374	349	3.34e-50	171
k141_622813_34	SARG|gb|CAL84423.1|ARO:3004146|cfrC	33.4	341	374	344	5.81e-50	170
k141_743258_5	megares|MEG_8288|Drugs|beta-lactam|Mutant_porin_proteins|OMPA_1	36.7	357	353	374	1.25e-59	195
k141_743258_5	CARD|gb|CDO13836.1|ARO:3005044|OmpA	36.7	357	353	374	1.25e-59	195
k141_45282_7	SARG|gi|672386269|gb|AIJ27535.1|	25.3	454	527	639	1.41e-35	139
k141_45282_7	SARG|AAR29485	25.4	453	527	639	2.58e-35	139
k141_45282_7	SARG|gi|544707441|ref|WP_021137831.1|	25.4	453	527	639	2.58e-35	139
k141_45282_7	megares|MEG_7165|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.2	449	527	639	8.63e-35	137
k141_45282_7	megares|MEG_7164|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.2	449	527	639	2.13e-34	136
k141_45282_7	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.1	447	527	639	7.08e-34	134
k141_45282_7	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.5	444	527	639	2.35e-33	133
k141_45282_7	SARG|AJ295238.gene.p01	24.5	444	527	639	3.16e-33	132
k141_45282_7	NCBI|WP_032490535.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	25.5	451	527	639	5.75e-33	132
k141_45282_7	SARG|ZP_03624201	24.7	449	527	639	1.41e-32	130
k141_45282_10	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	32.3	226	306	346	5.30e-20	87.8
k141_45282_25	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	561	650	655	7.95e-95	305
k141_45282_25	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	561	650	655	7.95e-95	305
k141_45282_25	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	3.06e-94	303
k141_45282_25	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	4.29e-94	303
k141_45282_25	SARG|gb|AKA86814|ARO:3003746|optrA	34.9	561	650	655	4.29e-94	303
k141_45282_25	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	6.00e-94	302
k141_45282_25	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	1.18e-93	301
k141_45282_25	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	1.18e-93	301
k141_45282_25	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	1.18e-93	301
k141_45282_25	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.9	561	650	655	1.18e-93	301
k141_45282_38	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	44.7	619	660	633	6.72e-190	550
k141_45282_38	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	28.3	441	660	664	1.67e-38	150
k141_45282_38	SARG|gb|CCC86795.1|ARO:3001209|mecC	28.3	441	660	665	4.12e-38	149
k141_45282_38	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	28.3	515	660	665	2.44e-37	147
k141_45282_38	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	28.4	443	660	665	1.93e-36	144
k141_45282_39	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	34.0	159	157	159	2.46e-28	101
k141_67198_26	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	22.2	977	864	1107	2.56e-18	89.4
k141_67198_26	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	22.2	977	864	1107	2.56e-18	89.4
k141_923366_5	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	61.9	42	319	346	4.59e-09	55.8
k141_386344_6	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	34.6	694	642	703	1.34e-111	350
k141_286318_7	CARD|gb|AAC16242.1|ARO:3005069|rsmA	66.7	54	69	61	3.04e-22	79.7
k141_47349_1	SARG|gb|MBY8651252.1|ARO:3007190|vanX_in_vanP_cl	45.7	199	291	202	3.89e-64	199
k141_47349_1	SARG|gi|748291568|ref|WP_039833226.1|	42.6	197	291	202	1.19e-54	175
k141_47349_1	SARG|AAD42185	40.7	199	291	202	1.35e-53	172
k141_47349_1	SARG|AAX19285	42.1	197	291	202	1.90e-53	172
k141_47349_1	megares|MEG_7412|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_3	42.1	197	291	205	2.08e-53	172
k141_47349_1	SARG|gi|740152778|ref|WP_037997107.1|	42.1	197	291	209	2.35e-53	172
k141_47349_1	NCBI|WP_063856768.1|1|1|vanX-Ac1|vanX-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase_VanX-Ac1|AMR|glycopeptide	42.7	199	291	204	4.04e-53	171
k141_47349_1	SARG|AAY52006	41.6	197	291	202	5.37e-53	171
k141_47349_1	megares|MEG_7409|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_3	41.6	197	291	205	5.88e-53	171
k141_47349_1	SARG|ABS72059	40.2	199	291	202	7.59e-53	170
k141_387180_1	SARG|FJ872411.1.gene41.p01	31.5	343	331	352	1.33e-42	149
k141_387180_1	SARG|gb|ABX54687.1|ARO:3002910|vanL	33.4	347	331	349	1.74e-42	149
k141_387180_1	SARG|gi|498467695|ref|WP_010773051.1|	31.5	343	331	352	2.60e-42	149
k141_387180_1	SARG|gi|1028100553|ref|WP_063856688.1|	32.6	341	331	343	8.98e-40	142
k141_387180_1	SARG|gi|777763073|gb|AJY53584.1|	31.3	332	331	343	2.45e-39	140
k141_387180_1	SARG|gi|751652141|ref|WP_041119007.1|	32.6	340	331	343	9.35e-39	139
k141_387180_1	SARG|AF162694.1.gene2.p01	32.3	341	331	343	9.35e-39	139
k141_387180_1	SARG|gi|257803688|gb|EEV32510.1|	32.3	341	331	344	9.55e-39	139
k141_387180_1	SARG|gi|1028100552|ref|WP_063856687.1|	32.0	341	331	343	3.56e-38	137
k141_387180_1	SARG|gi|748755610|ref|WP_040013725.1|	32.0	341	331	343	4.97e-38	137
k141_387180_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.0	435	589	441	4.77e-32	127
k141_346965_3	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.4	775	936	1024	1.45e-101	339
k141_346965_3	SARG|gb|CAA53189|ARO:3000521|mupA	29.4	775	936	1024	1.45e-101	339
k141_346965_3	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	29.4	775	936	1024	2.01e-101	339
k141_346965_3	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.4	775	936	1024	2.01e-101	339
k141_346965_3	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	25.1	852	936	1107	3.98e-72	258
k141_346965_3	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	25.1	852	936	1107	3.98e-72	258
k141_804704_4	SARG|gb|APB03219.1|ARO:3003986|TaeA	31.4	653	611	648	9.73e-94	300
k141_804704_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	3.47e-66	227
k141_804704_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	6.67e-66	226
k141_804704_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	6.67e-66	226
k141_804704_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	6.67e-66	226
k141_804704_4	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	6.67e-66	226
k141_804704_4	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	6.67e-66	226
k141_804704_4	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	6.67e-66	226
k141_804704_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	1.28e-65	226
k141_804704_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	533	611	655	1.28e-65	226
k141_804704_5	SARG|gb|APB03216.1|ARO:3003982|LlmA	32.0	128	728	287	2.39e-07	52.0
k141_926118_17	SARG|gb|APB03216.1|ARO:3003982|LlmA	31.1	119	397	287	8.49e-12	64.3
k141_730223_6	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.9	113	336	1197	1.75e-10	61.2
k141_730223_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.7	104	336	229	4.17e-06	46.2
k141_550142_7	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.3	342	938	1197	1.15e-37	152
k141_550142_7	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.8	212	938	467	8.57e-16	80.1
k141_550142_31	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	35.1	370	360	366	4.57e-51	173
k141_550142_31	SARG|gi|498467693|ref|WP_010773049.1|	34.7	369	360	700	4.32e-49	174
k141_550142_31	SARG|FJ872411.1.gene43.p01	33.7	362	360	702	9.40e-46	165
k141_550142_31	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	31.7	369	360	712	2.19e-43	158
k141_550142_31	SARG|AAY67970	32.0	372	360	698	2.49e-42	155
k141_550142_31	SARG|AF162694.1.gene4.p01	32.2	366	360	698	3.41e-42	155
k141_550142_31	SARG|gi|657686198|ref|WP_029487032.1|	32.2	366	360	698	3.41e-42	155
k141_550142_31	SARG|JF802084.2.gene3.p01	31.5	356	360	700	5.83e-41	151
k141_550142_31	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	33.3	285	360	656	9.16e-34	130
k141_550142_35	SARG|gb|APB03219.1|ARO:3003986|TaeA	38.4	539	555	648	6.96e-116	356
k141_550142_35	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.0	540	555	655	3.57e-70	236
k141_550142_35	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.0	540	555	655	3.57e-70	236
k141_550142_35	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.0	540	555	655	3.57e-70	236
k141_550142_35	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.0	540	555	655	3.57e-70	236
k141_550142_35	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.0	540	555	655	3.57e-70	236
k141_550142_35	SARG|gb|AKA86814|ARO:3003746|optrA	32.0	540	555	655	3.57e-70	236
k141_550142_35	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.1	542	555	655	1.34e-69	235
k141_550142_35	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	540	555	655	1.34e-69	235
k141_550142_35	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	540	555	655	1.34e-69	235
k141_869958_6	SARG|gi|835330218|ref|WP_047457825.1|	47.0	219	228	648	3.59e-62	204
k141_869958_6	SARG|YP_001453760	47.0	219	228	648	3.59e-62	204
k141_869958_6	SARG|gi|565651791|ref|WP_023899061.1|	45.9	222	228	647	9.94e-61	200
k141_869958_6	SARG|gi|754927849|ref|WP_042284850.1|	45.7	219	228	648	1.01e-60	200
k141_869958_6	SARG|gi|974588181|ref|WP_059178476.1|	46.4	222	228	646	2.66e-60	199
k141_869958_6	SARG|gi|763399392|ref|WP_044256358.1|	45.2	219	228	648	2.74e-60	199
k141_869958_6	SARG|YP_001176128	46.8	222	228	646	3.72e-60	198
k141_869958_6	SARG|gi|671541568|ref|WP_031525212.1|	45.9	220	228	648	3.83e-60	198
k141_869958_6	SARG|gi|749017716|ref|WP_040076354.1|	46.4	222	228	646	5.19e-60	198
k141_869958_6	SARG|gi|779958642|ref|WP_045406003.1|	46.4	222	228	646	5.19e-60	198
k141_869958_12	SARG|gb|AAK76136.1|ARO:3000025|patB	33.3	577	606	588	1.02e-93	298
k141_869958_12	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.1	522	606	664	2.91e-90	291
k141_869958_12	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.9	524	606	582	4.17e-90	289
k141_869958_12	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.4	569	606	579	1.36e-85	277
k141_869958_12	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.6	576	606	579	1.91e-85	276
k141_869958_12	SARG|gi|1045390184|ref|WP_065479071.1|	33.1	547	606	605	1.14e-81	267
k141_869958_12	SARG|gi|951183771|ref|WP_057661487.1|	33.1	547	606	603	1.59e-80	264
k141_869958_12	SARG|gi|664042835|ref|WP_030582300.1|	32.4	544	606	604	1.63e-80	264
k141_869958_12	SARG|gi|695891735|ref|WP_032792824.1|	33.1	547	606	603	3.11e-80	263
k141_869958_12	SARG|gi|913055317|ref|WP_050357634.1|	33.1	547	606	603	4.35e-80	263
k141_869958_13	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.9	574	578	575	4.21e-111	342
k141_869958_13	SARG|gb|AAK76137.1|ARO:3000024|patA	34.5	557	578	564	6.52e-103	321
k141_869958_13	SARG|gi|917229923|ref|WP_051836635.1|	32.3	564	578	620	1.01e-75	251
k141_869958_13	SARG|gi|772774655|ref|WP_045322518.1|	31.9	564	578	620	5.35e-75	249
k141_869958_13	SARG|gi|860594225|ref|WP_048475168.1|	32.1	564	578	620	7.47e-75	249
k141_869958_13	SARG|gi|496018010|ref|WP_008742581.1|	32.3	564	578	623	1.11e-74	248
k141_869958_13	SARG|gi|926351744|ref|WP_053683383.1|	32.1	573	578	648	1.34e-74	249
k141_869958_13	SARG|gi|517347347|ref|WP_018522839.1|	31.5	568	578	601	1.88e-74	247
k141_869958_13	SARG|gi|662129758|ref|WP_030081404.1|	31.9	568	578	605	2.05e-74	247
k141_869958_13	SARG|gi|919568551|ref|WP_052871170.1|	32.1	564	578	620	2.83e-74	247
k141_273195_24	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.0	394	702	1197	1.22e-41	162
k141_273195_24	CARD|gb|AEX49906.1|ARO:3003583|basS	27.9	269	702	477	4.59e-18	86.7
k141_273195_24	SARG|gb|AAG05187.1|ARO:3005067|ParS	26.0	204	702	428	3.34e-09	58.5
k141_273195_25	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.4	104	468	229	6.36e-11	61.2
k141_273195_25	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.8	115	468	232	1.20e-10	60.5
k141_273195_25	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.8	115	468	232	1.20e-10	60.5
k141_273195_25	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.4	134	468	1197	5.49e-10	60.8
k141_273195_25	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.3	138	468	232	7.23e-10	58.2
k141_273195_25	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.7	127	468	231	1.75e-09	57.0
k141_273195_25	CARD|gb|ADM92605.1|ARO:3000553|adeR	27.8	126	468	247	2.09e-09	57.0
k141_273195_25	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.6	104	468	225	2.19e-09	56.6
k141_273195_25	CARD|gb|AAC73788.1|ARO:3003841|kdpE	35.6	104	468	225	2.19e-09	56.6
k141_273195_25	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.2	116	468	228	2.27e-09	56.6
k141_273620_2	CARD|gb|AIA35096.1|ARO:3005059|LptD	30.1	773	855	782	8.23e-97	319
k141_194046_24	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.3	189	366	258	8.65e-23	95.1
k141_194046_24	SARG|gi|921979807|ref|WP_053271336.1|	24.7	348	366	648	2.35e-18	85.5
k141_194046_24	SARG|gi|948137056|ref|WP_056795395.1|	27.9	204	366	602	4.32e-11	63.2
k141_194046_24	SARG|gi|517381192|ref|WP_018555350.1|	27.7	202	366	602	2.32e-09	57.8
k141_194046_24	SARG|gb|AAK76136.1|ARO:3000025|patB	24.6	183	366	588	1.67e-08	55.1
k141_194046_24	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.3	165	366	574	2.90e-08	54.3
k141_194046_24	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	27.9	172	366	461	1.41e-07	52.0
k141_194046_24	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.4	201	366	550	4.79e-07	50.4
k141_194046_24	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	42.2	64	366	461	1.80e-06	48.5
k141_274025_1	CARD|gb|AIA35096.1|ARO:3005059|LptD	29.7	770	839	782	4.31e-94	311
k141_274025_4	NCBI|WP_041079981.1|1|1|erm(44)v|erm(44)v|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(44)v|AMR|multidrug	25.5	247	290	243	3.54e-15	72.4
k141_274025_4	megares|MEG_2769|Drugs|MLS|23S_rRNA_methyltransferases|ERM_1	25.5	247	290	251	3.95e-15	72.4
k141_274025_4	NCBI|WP_139847607.1|1|1|erm(53)|erm(53)|target_modification|2|MACROLIDE|MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(53)|AMR|macrolide	28.4	141	290	300	4.34e-14	70.1
k141_274025_4	SARG|gb|CDL65151.1|ARO:3003971|erm(44)	26.9	186	290	243	2.84e-13	67.0
k141_274025_4	SARG|BAC53825	22.6	252	290	243	1.01e-07	50.8
k141_274025_4	SARG|P0A0H1	22.2	252	290	243	1.46e-06	47.4
k141_274025_7	SARG|gb|ABO40886.1|ARO:3004645|dfrI	42.4	165	171	191	8.07e-32	112
k141_274025_7	SARG|CAL48457	39.8	166	171	183	1.44e-27	100
k141_274025_7	NCBI|WP_140423286.1|1|1|dfrA17|dfrA17|insensitivity|2|||diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA17|AMR|diaminopyrimidine	25.5	161	171	157	9.28e-13	61.6
k141_274025_7	megares|MEG_2508|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	25.5	161	171	157	9.28e-13	61.6
k141_214386_2	SARG|gi|558088995|ref|WP_023481339.1|	34.5	440	460	457	6.76e-81	256
k141_214386_2	SARG|YP_001445425	33.7	439	460	456	3.63e-80	254
k141_214386_2	SARG|Q8D9N8	32.6	433	460	456	5.13e-76	244
k141_214386_2	SARG|gi|754952496|ref|WP_042308660.1|	34.9	439	460	457	5.27e-76	244
k141_214386_2	SARG|gi|1002398650|ref|WP_061381408.1|	34.6	439	460	457	5.27e-76	244
k141_214386_2	SARG|gi|757799242|ref|WP_043016444.1|	34.3	437	460	457	7.41e-76	243
k141_214386_2	SARG|gi|696368298|ref|WP_032943310.1|	34.3	437	460	457	1.47e-75	243
k141_214386_2	SARG|NP_934523	32.6	433	460	456	2.01e-75	242
k141_214386_2	SARG|gi|851908704|ref|WP_048214273.1|	33.1	435	460	457	2.06e-75	242
k141_214386_2	SARG|gi|780027477|ref|WP_045442423.1|	34.2	438	460	457	2.90e-75	242
k141_852160_9	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.4	581	616	582	1.47e-107	335
k141_852160_9	SARG|gi|664556405|ref|WP_031071225.1|	30.3	587	616	602	3.88e-87	282
k141_852160_9	SARG|gi|926351744|ref|WP_053683383.1|	32.5	511	616	648	6.21e-86	280
k141_852160_9	SARG|gi|748767925|ref|WP_040019608.1|	31.2	596	616	623	1.39e-84	276
k141_852160_9	SARG|gi|663350985|ref|WP_030349761.1|	30.7	548	616	613	4.22e-84	274
k141_852160_9	SARG|gi|953808775|ref|WP_058042812.1|	31.1	543	616	608	1.44e-83	273
k141_852160_9	SARG|gi|558888514|ref|WP_023543283.1|	29.0	586	616	615	4.63e-83	271
k141_852160_9	SARG|AF170880.4.gene1.p01	29.2	583	616	615	9.06e-83	271
k141_852160_9	SARG|gi|817122037|ref|WP_046494699.1|	30.6	540	616	613	2.47e-81	267
k141_852160_9	SARG|gi|664304639|ref|WP_030834011.1|	30.5	551	616	614	1.45e-78	259
k141_136899_2	SARG|NP_348076	27.6	688	701	652	1.15e-79	266
k141_136899_2	SARG|YP_002850805	28.6	690	701	652	6.02e-79	264
k141_136899_2	SARG|ZP_02952732	28.1	687	701	652	1.64e-77	260
k141_136899_2	SARG|ZP_02632674	28.1	687	701	660	1.94e-77	260
k141_136899_2	SARG|L20800.gene.p01	28.1	687	701	652	8.53e-77	258
k141_136899_2	SARG|L42544.gene.p01	28.0	672	701	651	6.04e-75	253
k141_136899_2	SARG|AAV80410	27.8	672	701	651	8.37e-74	250
k141_136899_2	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.7	685	701	641	5.96e-66	228
k141_136899_2	SARG|AAZ79478	26.7	685	701	657	8.02e-66	228
k141_136899_2	SARG|AJ514254.gene.p01	25.4	682	701	640	4.09e-65	226
k141_136899_9	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.4	219	243	343	1.82e-27	106
k141_136899_9	SARG|gb|AAA26793|ARO:3003748|oleC	30.0	223	243	325	7.21e-26	102
k141_136899_9	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	30.5	220	243	325	1.00e-25	101
k141_136899_9	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	29.7	212	243	293	1.10e-19	84.7
k141_136899_9	SARG|gi|895981299|ref|WP_049056431.1|	24.9	213	243	648	5.63e-15	72.8
k141_136899_9	SARG|gi|823281237|ref|WP_047037467.1|	24.9	213	243	648	5.63e-15	72.8
k141_136899_9	SARG|gi|895967513|ref|WP_049046752.1|	24.9	213	243	648	5.63e-15	72.8
k141_136899_9	SARG|gi|779903733|ref|WP_045374054.1|	24.9	213	243	648	5.63e-15	72.8
k141_136899_9	SARG|gb|AAK76137.1|ARO:3000024|patA	24.2	219	243	564	2.92e-12	64.7
k141_136899_9	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.0	221	243	351	1.95e-10	58.9
k141_813361_7	SARG|gb|ADZ12699.1|ARO:3005091|RanA	28.8	243	274	258	4.00e-30	112
k141_813361_7	SARG|gb|AAK76136.1|ARO:3000025|patB	23.6	225	274	588	2.93e-15	74.3
k141_813361_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	22.6	226	274	664	1.17e-12	66.6
k141_813361_7	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.2	237	274	582	1.50e-12	66.2
k141_813361_7	SARG|gi|739906046|ref|WP_037756452.1|	24.9	229	274	620	9.04e-12	63.9
k141_813361_7	SARG|gi|516574297|ref|WP_017949361.1|	24.9	229	274	620	9.04e-12	63.9
k141_813361_7	SARG|gi|493394434|ref|WP_006350564.1|	24.2	256	274	602	1.61e-11	63.2
k141_813361_7	SARG|AF170880.4.gene1.p01	25.9	263	274	615	1.71e-10	60.1
k141_813361_7	SARG|gi|926400371|ref|WP_053728483.1|	25.4	236	274	603	9.83e-10	57.8
k141_813361_7	SARG|gi|558888514|ref|WP_023543283.1|	25.5	263	274	615	9.91e-10	57.8
k141_813361_16	SARG|gi|671541568|ref|WP_031525212.1|	30.0	120	951	648	6.32e-08	55.5
k141_813361_19	SARG|gb|AAK76136.1|ARO:3000025|patB	33.7	255	870	588	1.73e-30	126
k141_813361_19	SARG|gb|CDO61516.1|ARO:3003949|efrB	31.1	251	870	362	1.03e-27	114
k141_813361_19	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.7	246	870	664	3.24e-27	117
k141_813361_19	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.8	233	870	575	1.06e-24	108
k141_813361_19	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.6	253	870	579	1.09e-24	108
k141_813361_19	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.6	253	870	579	5.94e-24	106
k141_813361_19	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	31.3	208	870	578	2.43e-23	104
k141_813361_19	SARG|gi|491270241|ref|WP_005128370.1|	26.8	220	870	648	8.78e-15	77.4
k141_813361_19	SARG|gi|851902043|ref|WP_048212057.1|	26.8	220	870	648	8.78e-15	77.4
k141_813361_19	SARG|gi|992380339|ref|WP_061067665.1|	26.8	220	870	648	8.78e-15	77.4
k141_813361_20	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	33.5	236	731	578	5.24e-35	139
k141_813361_20	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.3	245	731	579	1.79e-33	135
k141_813361_20	SARG|gi|663342223|ref|WP_030341347.1|	24.0	488	731	605	9.45e-33	133
k141_813361_20	SARG|gi|759527374|ref|WP_043247487.1|	24.0	488	731	605	9.45e-33	133
k141_813361_20	SARG|gi|664194237|ref|WP_030727956.1|	24.0	488	731	605	9.45e-33	133
k141_813361_20	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.8	238	731	579	1.03e-32	132
k141_813361_20	SARG|gi|664556405|ref|WP_031071225.1|	24.8	487	731	602	1.24e-32	132
k141_813361_20	SARG|gi|664317010|ref|WP_030845774.1|	24.0	488	731	605	1.26e-32	132
k141_813361_20	SARG|gi|663286402|ref|WP_030292859.1|	24.0	488	731	605	1.26e-32	132
k141_813361_20	SARG|gi|926286457|ref|WP_053623344.1|	23.8	488	731	605	1.69e-32	132
k141_813361_24	SARG|gi|694064328|ref|WP_032410816.1|	30.4	224	221	646	1.41e-31	120
k141_813361_24	SARG|gi|500194536|ref|WP_011867743.1|	30.0	220	221	306	1.15e-22	92.4
k141_813361_24	SARG|gi|445996732|ref|WP_000074587.1|	27.7	220	221	309	2.28e-21	89.0
k141_813361_24	SARG|gi|507035724|ref|WP_016107411.1|	27.3	220	221	309	6.07e-21	87.8
k141_813361_24	SARG|gi|445996698|ref|WP_000074553.1|	27.3	220	221	309	6.07e-21	87.8
k141_813361_24	SARG|gi|445996697|ref|WP_000074552.1|	27.3	220	221	309	8.40e-21	87.4
k141_813361_24	SARG|gi|445996696|ref|WP_000074551.1|	27.3	220	221	309	8.40e-21	87.4
k141_813361_24	SARG|gi|542061059|gb|ERI11611.1|	28.1	221	221	316	9.16e-21	87.4
k141_813361_24	SARG|gi|447057510|ref|WP_001134766.1|	28.2	220	221	309	3.08e-20	85.9
k141_813361_24	SARG|gi|500448961|gb|EOP61695.1|	29.3	205	221	306	4.11e-20	85.5
k141_874943_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.9	185	361	362	6.30e-11	62.0
k141_257669_9	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	47.5	61	304	346	4.30e-13	67.8
k141_39035_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.2	121	127	228	1.15e-13	63.9
k141_39035_10	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.0	122	127	1197	4.49e-13	63.5
k141_98513_12	SARG|gi|664352659|ref|WP_030880307.1|	42.0	226	235	601	1.60e-49	169
k141_98513_12	SARG|gi|664100597|ref|WP_030638327.1|	42.0	226	235	601	1.60e-49	169
k141_98513_12	SARG|gi|505389066|ref|WP_015576168.1|	42.0	226	235	601	1.60e-49	169
k141_98513_12	SARG|gi|503923650|ref|WP_014157644.1|	42.0	226	235	601	1.60e-49	169
k141_98513_12	SARG|gi|662754041|ref|WP_030125200.1|	42.0	226	235	601	2.23e-49	169
k141_98513_12	SARG|gi|702897513|ref|WP_033300957.1|	41.6	226	235	601	3.09e-49	169
k141_98513_12	SARG|gi|754608317|ref|WP_041998010.1|	43.3	217	235	612	1.32e-48	167
k141_98513_12	SARG|gi|739906046|ref|WP_037756452.1|	41.4	222	235	620	1.45e-48	167
k141_98513_12	SARG|gi|947982677|ref|WP_056642336.1|	42.6	223	235	626	1.55e-48	167
k141_98513_12	SARG|gi|944009777|ref|WP_055601444.1|	44.1	220	235	628	1.59e-48	167
